Skip to main content
SpringerLink
Log in

TP53 Somatic Mutations: Prognostic and Predictive Value in Human Cancers

  • Chapter
  • First Online:
p53 in the Clinics

Abstract

The tumor suppressor gene TP53 (OMIM #191117) is one of the most frequently altered genes in human cancers. Somatic gene mutations are the preferred mode of inactivation in many cancer types. These mutations have been shown, in various experimental models, to promote cell proliferation and resistance to anti-neoplastic effects of radio- and chemotherapeutic agents. It was thus expected that TP53 mutations may be useful prognostic and predictive markers in cancer. While a prognostic marker provides information on the risk of relapse and death independently of treatment, a predictive marker provides information on the potential benefit of a specific treatment. Many studies have investigated, in various clinical settings, the prognostic and predictive value of TP53 mutation status in cancer patients. Despite many studies showing a poor prognosis associated with TP53-mutated status, no consensus results have been produced that could support clinical applications. Here, we review these studies, in particular those performed in the context of specific treatment regimen.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Alsner J, Yilmaz M, Guldberg P, Hansen LL, Overgaard J (2000) Heterogeneity in the clinical phenotype of TP53 mutations in breast cancer patients. Clin Cancer Res 6:3923–3931

    PubMed  CAS  Google Scholar 

  • Andersson J, Larsson L, Klaar S, Holmberg L, Nilsson J, Inganas M, Carlsson G, Ohd J, Rudenstam CM, Gustavsson B, Bergh J (2005) Worse survival for TP53 (p53)-mutated breast cancer patients receiving adjuvant CMF. Ann Oncol 16:743–748

    Article  PubMed  CAS  Google Scholar 

  • Bergamaschi D, Gasco M, Hiller L, Sullivan A, Syed N, Trigiante G, Yulug I, Merlano M, Numico G, Comino A, Attard M, Reelfs O, Gusterson B, Bell AK, Heath V, Tavassoli M, Farrell PJ, Smith P, Lu X, Crook T (2003) p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis. Cancer Cell 3:387–402

    Article  PubMed  CAS  Google Scholar 

  • Bergh J, Norberg T, Sjogren S, Lindgren A, Holmberg L (1995) Complete sequencing of the p53 gene provides prognostic information in breast cancer patients, particularly in relation to adjuvant systemic therapy and radiotherapy. Nat Med 1:1029–1034

    Article  PubMed  CAS  Google Scholar 

  • Berns EM, Foekens JA, Vossen R, Look MP, Devilee P, Henzen-Logmans SC, van Staveren IL, van Putten WL, Inganas M, Meijer-van Gelder ME, Cornelisse C, Claassen CJ, Portengen H, Bakker B, Klijn JG (2000) Complete sequencing of TP53 predicts poor response to systemic therapy of advanced breast cancer. Cancer Res 60:2155–2162

    PubMed  CAS  Google Scholar 

  • Bertheau P, Turpin E, Rickman DS, Espie M, de RA, Feugeas JP, Plassa LF, Soliman H, Varna M, de RA, Lehmann-Che J, Beuzard Y, Marty M, Misset JL, Janin A, de TH (2007) Exquisite sensitivity of TP53 mutant and basal breast cancers to a dose-dense epirubicin-cyclophosphamide regimen. PLoS Med 4:90

    Article  Google Scholar 

  • Bonnefoi H, Piccart M, Bogaerts J, Mauriac L, Fumoleau P, Brain E, Petit T, Rouanet P, Jassem J, Blot E, Zaman K, Cufer T, Lortholary A, Lidbrink E, Andre S, Litiere S, Lago LD, Becette V, Cameron DA, Bergh J, Iggo R (2011) TP53 status for prediction of sensitivity to taxane versus non-taxane neoadjuvant chemotherapy in breast cancer (EORTC 10994/BIG 1–00): a ­randomised phase 3 trial. Lancet Oncol 12:527–539

    Article  PubMed  CAS  Google Scholar 

  • Borresen AL, Andersen TI, Eyfjord JE, Cornelis RS, Thorlacius S, Borg A, Johansson U, Theillet C, Scherneck S, Hartman S (1995) TP53 mutations and breast cancer prognosis: particularly poor survival rates for cases with mutations in the zinc-binding domains. Genes Chromosomes Cancer 14:71–75

    Article  PubMed  CAS  Google Scholar 

  • Bougeard G, Baert-Desurmont S, Tournier I, Vasseur S, Martin C, Brugieres L, Chompret A, Bressac-de Paillerets B, Stoppa-Lyonnet D, Bonaiti-Pellie C, Frebourg T (2006) Impact of the MDM2 SNP309 and p53 Arg72Pro polymorphism on age of tumour onset in Li-Fraumeni syndrome. J Med Genet 43:531–533

    Article  PubMed  CAS  Google Scholar 

  • Casson AG, Evans SC, Gillis A, Porter GA, Veugelers P, Darnton SJ, Guernsey DL, Hainaut P (2003) Clinical implications of p53 tumor suppressor gene mutation and protein expression in esophageal adenocarcinomas: results of a ten-year prospective study. J Thorac Cardiovasc Surg 125:1121–1131

    Article  PubMed  CAS  Google Scholar 

  • Chen YJ, Hakin-Smith V, Teo M, Xinarianos GE, Jellinek DA, Carroll T, McDowell D, MacFarlane MR, Boet R, Baguley BC, Braithwaite AW, Reddel RR, Royds JA (2006) Association of mutant TP53 with alternative lengthening of telomeres and favorable prognosis in glioma. Cancer Res 66:6473–6476

    Article  PubMed  CAS  Google Scholar 

  • Chrisanthar R, Knappskog S, Lokkevik E, Anker G, Ostenstad B, Lundgren S, Berge EO, Risberg T, Mjaaland I, Maehle L, Engebretsen LF, Lillehaug JR, Lonning PE (2008) CHEK2 mutations affecting kinase activity together with mutations in TP53 indicate a functional pathway associated with resistance to epirubicin in primary breast cancer. PLoS One 3:e3062

    Article  PubMed  Google Scholar 

  • Chrisanthar R, Knappskog S, Lokkevik E, Anker G, Ostenstad B, Lundgren S, Risberg T, Mjaaland I, Skjonsberg G, Aas T, Schlichting E, Fjosne HE, Nysted A, Lillehaug JR, Lonning PE (2011) Predictive and prognostic impact of TP53 mutations and MDM2 promoter genotype in primary breast cancer patients treated with epirubicin or paclitaxel. PLoS One 6:e19249

    Article  PubMed  CAS  Google Scholar 

  • Cimoli G, Malacarne D, Ponassi R, Valenti M, Alberti S, Parodi S (2004) Meta-analysis of the role of p53 status in isogenic systems tested for sensitivity to cytotoxic antineoplastic drugs1. Biochim Biophys Acta 1705:103–120

    PubMed  CAS  Google Scholar 

  • Concin N, Hofstetter G, Berger A, Gehmacher A, Reimer D, Watrowski R, Tong D, Schuster E, Hefler L, Heim K, Mueller-Holzner E, Marth C, Moll UM, Zeimet AG, Zeillinger R (2005) Clinical relevance of dominant-negative p73 isoforms for responsiveness to chemotherapy and survival in ovarian cancer: evidence for a crucial p53-p73 cross-talk in vivo. Clin Cancer Res 11:8372–8383

    Article  PubMed  CAS  Google Scholar 

  • de Anta JM, Jassem E, Rosell R, Martinez-Roca M, Jassem J, Martinez-Lopez E, Monzo M, Sanchez-Hernandez JJ, Moreno I, Sanchez-Cespedes M (1997) TP53 mutational pattern in Spanish and Polish non-small cell lung cancer patients: null mutations are associated with poor prognosis. Oncogene 15:2951–2958

    Article  PubMed  Google Scholar 

  • Dumaz N, Brougard C, Sarasin A, Daya-Grosjean L (1993) Specific UV-induced mutation spectrum in the p53 gene of skin tumors from DNA-repair-defiicent xeroderma pigmentosum patients. Proc Natl Acad Sci USA 90:10529–10533

    Article  PubMed  CAS  Google Scholar 

  • Felsberg J, Rapp M, Loeser S, Fimmers R, Stummer W, Goeppert M, Steiger HJ, Friedensdorf B, Reifenberger G, Sabel MC (2009) Prognostic significance of molecular markers and extent of resection in primary glioblastoma patients. Clin Cancer Res 15:6683–6693

    Article  PubMed  CAS  Google Scholar 

  • Forconi F, Sozzi E, Cencini E, Zaja F, Intermesoli T, Stelitano C, Rigacci L, Gherlinzoni F, Cantaffa R, Baraldi A, Gallamini A, Zaccaria A, Pulsoni A, Gobbi M, Tassi M, Raspadori D, Leoncini L, Rinaldi A, Sabattini E, Bertoni F, Pileri SA, Lauria F (2009) Hairy cell leukemias with unmutated IGHV genes define the minor subset refractory to single-agent cladribine and with more aggressive behavior. Blood 114:4696–4702

    Article  PubMed  CAS  Google Scholar 

  • Furihata M, Takeuchi T, Matsumoto M, Kurabayashi A, Ohtsuki Y, Terao N, Kuwahara M, Shuin T (2002) p53 mutation arising in Arg72 allele in the tumorigenesis and development of carcinoma of the urinary tract. Clin Cancer Res 8:1192–1195

    PubMed  CAS  Google Scholar 

  • Geisler S, Borresen-Dale AL, Johnsen H, Aas T, Geisler J, Akslen LA, Anker G, Lonning PE (2003) TP53 gene mutations predict the response to neoadjuvant treatment with 5-fluorouracil and mitomycin in locally advanced breast cancer. Clin Cancer Res 9:5582–5588

    PubMed  CAS  Google Scholar 

  • Geisler S, Lonning PE, Aas T, Johnsen H, Fluge O, Haugen DF, Lillehaug JR, Akslen LA, Borresen-Dale AL (2001) Influence of TP53 gene alterations and c-erbB-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer. Cancer Res 61:2505–2512

    PubMed  CAS  Google Scholar 

  • Gluck S, Ross JS, Royce M, McKenna EF, Jr., Perou CM, Avisar E, Wu L (2011) TP53 genomics predict higher clinical and pathologic tumor response in operable early-stage breast cancer treated with docetaxel-capecitabine +/− trastuzumab. Breast Cancer Res Treat, Epub ahead of print

    Google Scholar 

  • Goan YG, Hsu HK, Chang HC, Chou YP, Chiang KH, Cheng JT (2005) Deregulated p21(WAF1) overexpression impacts survival of surgically resected esophageal squamous cell carcinoma patients. Ann Thorac Surg 80:1007–1016

    Article  PubMed  Google Scholar 

  • Hashimoto T, Tokuchi Y, Hayashi M, Kobayashi Y, Nishida K, Hayashi S, Ishikawa Y, Tsuchiya S, Nakagawa K, Hayashi J, Tsuchiya E (1999) p53 null mutations undetected by immunohistochemical staining predict a poor outcome with early-stage non-small cell lung carcinomas. Cancer Res 59:5572–5577

    PubMed  CAS  Google Scholar 

  • Havrilesky L, Darcy M, Hamdan H, Priore RL, Leon J, Bell J, Berchuck A (2003) Prognostic significance of p53 mutation and p53 overexpression in advanced epithelial ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol 21:3814–3825

    Article  PubMed  CAS  Google Scholar 

  • Holstege H, Joosse SA, van Oostrom CT, Nederlof PM, de VA, Jonkers J (2009) High incidence of protein-truncating TP53 mutations in BRCA1-related breast cancer 1. Cancer Res 69:3625–3633

    Article  PubMed  CAS  Google Scholar 

  • Inga A, Storici F, Darden TA, Resnick MA (2002) Differential transactivation by the p53 transcription factor is highly dependent on p53 level and promoter target sequence. Mol Cell Biol 22:8612–8625

    Article  PubMed  CAS  Google Scholar 

  • Kandioler D, Stamatis G, Eberhardt W, Kappel S, Zochbauer-Muller S, Kuhrer I, Mittlbock M, Zwrtek R, Aigner C, Bichler C, Tichy V, Hudec M, Bachleitner T, End A, Muller MR, Roth E, Klepetko W (2008) Growing clinical evidence for the interaction of the p53 genotype and response to induction chemotherapy in advanced non-small cell lung cancer. J Thorac Cardiovasc Surg 135:1036–1041

    Article  PubMed  CAS  Google Scholar 

  • Kandioler D, Zwrtek R, Ludwig C, Janschek E, Ploner M, Hofbauer F, Kuhrer I, Kappel S, Wrba F, Horvath M, Karner J, Renner K, Bergmann M, Karner-Hanusch J, Potter R, Jakesz R, Teleky B, Herbst F (2002) TP53 genotype but not p53 immunohistochemical result predicts response to preoperative short-term radiotherapy in rectal cancer. Ann Surg 235:493–498

    Article  PubMed  Google Scholar 

  • Kandioler-Eckersberger D, Kappel S, Mittlbock M, Dekan G, Ludwig C, Janschek E, Pirker R, Wolner E, Eckersberger F (1999) The TP53 genotype but not immunohistochemical result is predictive of response to cisplatin-based neoadjuvant therapy in stage III non-small cell lung cancer. J Thorac Cardiovasc Surg 117:744–750

    Article  PubMed  CAS  Google Scholar 

  • Kandioler-Eckersberger D, Ludwig C, Rudas M, Kappel S, Janschek E, Wenzel C, Schlagbauer-Wadl H, Mittlbock M, Gnant M, Steger G, Jakesz R (2000) TP53 mutation and p53 overexpression for prediction of response to neoadjuvant treatment in breast cancer patients. Clin Cancer Res 6:50–56

    PubMed  CAS  Google Scholar 

  • Katkoori VR, Jia X, Shanmugam C, Wan W, Meleth S, Bumpers H, Grizzle WE, Manne U (2009) Prognostic significance of p53 codon 72 polymorphism differs with race in colorectal adenocarcinoma. Clin Cancer Res 15:2406–2416

    Article  PubMed  CAS  Google Scholar 

  • Kato S, Han SY, Liu W, Otsuka K, Shibata H, Kanamaru R, Ishioka C (2003) Understanding the function-structure and function-mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis. Proc Natl Acad Sci USA 100:8424–8429

    Article  PubMed  CAS  Google Scholar 

  • Kihara C, Seki T, Furukawa Y, Yamana H, Kimura Y, van Schaardenburgh P, Hirata K, Nakamura Y (2000) Mutations in zinc-binding domains of p53 as a prognostic marker of esophageal-cancer patients. Jpn J Cancer Res 91:190–198

    Article  PubMed  CAS  Google Scholar 

  • Kucera E, Speiser P, Gnant M, Szabo L, Samonigg H, Hausmaninger H, Mittlbock M, Fridrik M, Seifert M, Kubista E, Reiner A, Zeillinger R, Jakesz R (1999) Prognostic significance of mutations in the p53 gene, particularly in the zinc-binding domains, in lymph node- and steroid receptor positive breast cancer patients. Austrian Breast Cancer Study Group. Eur J Cancer 35:398–405

    Article  PubMed  CAS  Google Scholar 

  • Langerod A, Bukholm IR, Bregard A, Lonning PE, Andersen TI, Rognum TO, Meling GI, Lothe RA, Borresen-Dale AL (2002) The TP53 codon 72 polymorphism may affect the function of TP53 mutations in breast carcinomas but not in colorectal carcinomas. Cancer Epidemiol Biomarkers Prev 11:1684–1688

    PubMed  CAS  Google Scholar 

  • Langerod A, Zhao H, Borgan O, Nesland JM, Bukholm IR, Ikdahl T, Karesen R, Borresen-Dale AL, Jeffrey SS (2007) TP53 mutation status and gene expression profiles are powerful prognostic markers of breast cancer. Breast Cancer Res 9:R30

    Article  PubMed  Google Scholar 

  • Lehmann-Che J, Andre F, Desmedt C, Mazouni C, Giacchetti S, Turpin E, Espie M, Plassa LF, Marty M, Bertheau P, Sotiriou C, Piccart M, Symmans WF, Pusztai L, de TH (2010) Cyclophosphamide dose intensification may circumvent anthracycline resistance of p53 mutant breast cancers1. Oncologist 15:246–252

    Article  PubMed  CAS  Google Scholar 

  • Lind H, Ekstrom PO, Ryberg D, Skaug V, Andreassen T, Stangeland L, Haugen A, Zienolddiny S (2007) Frequency of TP53 mutations in relation to Arg72Pro genotypes in non small cell lung cancer. Cancer Epidemiol Biomarkers Prev 16:2077–2081

    Article  PubMed  CAS  Google Scholar 

  • Lowe SW, Bodis S, McClatchey A, Remington L, Ruley HE, Fisher DE, Housman DE, Jacks T (1994) p53 status and the efficacy of cancer therapy in vivo. Science 266:807–810

    Article  PubMed  CAS  Google Scholar 

  • Marin MC, Jost CA, Brooks LA, Irwin MS, O’Nions J, Tidy JA, James N, McGregor JM, Harwood CA, Yulug IG, Vousden KH, Allday MJ, Gusterson B, Ikawa S, Hinds PW, Crook T, Kaelin WG Jr (2000) A common polymorphism acts as an intragenic modifier of mutant p53 behaviour. Nat Genet 25:47–54

    Article  PubMed  CAS  Google Scholar 

  • Miller LD, Smeds J, George J, Vega VB, Vergara L, Ploner A, Pawitan Y, Hall P, Klaar S, Liu ET, Bergh J (2005) An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. Proc Natl Acad Sci USA 102:13550–13555

    Article  PubMed  CAS  Google Scholar 

  • Miyaki M, Iijima T, Yasuno M, Kita Y, Hishima T, Kuroki T, Mori T (2002) High incidence of protein-truncating mutations of the p53 gene in liver metastases of colorectal carcinomas1. Oncogene 21:6689–6693

    Article  PubMed  CAS  Google Scholar 

  • Mollevi DG, Serrano T, Ginesta MM, Valls J, Torras J, Navarro M, Ramos E, Germa JR, Jaurrieta E, Moreno V, Figueras J, Capella G, Villanueva A (2007) Mutations in TP53 are a prognostic factor in colorectal hepatic metastases undergoing surgical resection1. Carcinogenesis 28:1241–1246

    Article  PubMed  CAS  Google Scholar 

  • Nelson HH, Wilkojmen M, Marsit CJ, Kelsey KT (2005) TP53 mutation, allelism and survival in non-small cell lung cancer. Carcinogenesis 26:1770–1773

    Article  PubMed  CAS  Google Scholar 

  • Nemunaitis J, Clayman G, Agarwala SS, Hrushesky W, Wells JR, Moore C, Hamm J, Yoo G, Baselga J, Murphy BA, Menander KA, Licato LL, Chada S, Gibbons RD, Olivier M, Hainaut P, Roth JA, Sobol RE, Goodwin WJ (2009) Biomarkers predict p53 gene therapy efficacy in recurrent squamous cell carcinoma of the head and neck. Clin Cancer Res 15:7719–7725

    Article  PubMed  CAS  Google Scholar 

  • O’Connor PM, Jackman J, Bae I, Myers TG, Fan S, Mutoh M, Scudiero DA, Monks A, Sausville EA, Weinstein JN, Friend S, Fornace AJ Jr, Kohn KW (1997) Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents. Cancer Res 57:4285–4300

    PubMed  Google Scholar 

  • Obata A, Eura M, Sasaki J, Saya H, Chikamatsu K, Tada M, Iggo RD, Yumoto E (2000) Clinical significance of p53 functional loss in squamous cell carcinoma of the oropharynx. Int J Cancer 89:187–193

    Article  PubMed  CAS  Google Scholar 

  • Oden-Gangloff A, Di Fiore F, Bibeau F, Lamy A, Bougeard G, Charbonnier F, Blanchard F, Tougeron D, Ychou M, Boissière F, Le Pessot F, Sabourin JC, Tuech JJ, Michel P, Frebourg T (2009) TP53 mutations predict disease control in metastatic colorectal cancer treated with cetuximab-based chemotherapy. Br J Cancer 100:1330–1335

    Article  PubMed  CAS  Google Scholar 

  • Olivier M, Hollstein M, Hainaut P (2010) TP53 mutations in human cancers: origins, consequences, and clinical use1. Cold Spring Harb Perspect Biol 2:a001008

    Article  PubMed  Google Scholar 

  • Olivier M, Hussain SP, Caron dF, Hainaut P, Harris CC (2004) TP53 mutation spectra and load: a tool for generating hypotheses on the etiology of cancer. IARC Sci Publ 157:247–270

    PubMed  Google Scholar 

  • Olivier M, Langerod A, Carrieri P, Bergh J, Klaar S, Eyfjord J, Theillet C, Rodriguez C, Lidereau R, Bieche I, Varley J, Bignon Y, Uhrhammer N, Winqvist R, Jukkola-Vuorinen A, Niederacher D, Kato S, Ishioka C, Hainaut P, Borresen-Dale AL (2006) The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer. Clin Cancer Res 12:1157–1167

    Article  PubMed  CAS  Google Scholar 

  • Petitjean A, Achatz MI, Borresen-Dale AL, Hainaut P, Olivier M (2007a) TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes. Oncogene 26:2157–2165

    Article  PubMed  CAS  Google Scholar 

  • Petitjean A, Mathe E, Kato S, Ishioka C, Tavtigian SV, Hainaut P, Olivier M (2007b) Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Hum Mutat 28:622–629

    Article  PubMed  CAS  Google Scholar 

  • Pfeifer GP (2000) p53 mutational spectra and the role of methylated CpG sequences. Mutat Res 450:155–166

    Article  PubMed  CAS  Google Scholar 

  • Poeta ML, Manola J, Goldwasser MA, Forastiere A, Benoit N, Califano JA, Ridge JA, Goodwin J, Kenady D, Saunders J, Westra W, Sidransky D, Koch WM (2007) TP53 mutations and survival in squamous-cell carcinoma of the head and neck1. N Engl J Med 357:2552–2561

    Article  PubMed  CAS  Google Scholar 

  • Rebischung C, Gerard JP, Gayet J, Thomas G, Hamelin R, Laurent-Puig P (2002) Prognostic value of P53 mutations in rectal carcinoma. Int J Cancer 100:131–135

    Article  PubMed  CAS  Google Scholar 

  • Reles A, Wen WH, Schmider A, Gee C, Runnebaum IB, Kilian U, Jones LA, El-Naggar A, Minguillon C, Schönborn I, Reich O, Kreienberg R, Lichtenegger W, Press MF (2001) Correlation of p53 mutations with resistance to platinum-based chemotherapy and shortened survival in ovarian cancer. Clin Cancer Res 7:2984–2997

    PubMed  CAS  Google Scholar 

  • Rose SL, Robertson AD, Goodheart MJ, Smith BJ, DeYoung BR, Buller RE (2003) The impact of p53 protein core domain structural alteration on ovarian cancer survival. Clin Cancer Res 9:4139–4144

    PubMed  CAS  Google Scholar 

  • Schneider-Stock R, Boltze C, Peters B, Szibor R, Landt O, Meyer F, Roessner A (2004) Selective loss of codon 72 proline p53 and frequent mutational inactivation of the retained arginine allele in colorectal cancer. Neoplasia 6:529–535

    Article  PubMed  CAS  Google Scholar 

  • Skaug V, Ryberg D, Kure EH, Arab MO, Stangeland L, Myking AO, Haugen A (2000) p53 mutations in defined structural and functional domains are related to poor clinical outcome in non-small cell lung cancer patients. Clin Cancer Res 6:1031–1037

    PubMed  CAS  Google Scholar 

  • Smith-Sorensen B, Kaern J, Holm R, Dorum A, Trope C, Borresen-Dale AL (1998) Therapy effect of either paclitaxel or cyclophosphamide combination treatment in patients with epithelial ovarian cancer and relation to TP53 gene status. Br J Cancer 78:375–381

    Article  PubMed  CAS  Google Scholar 

  • Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, Deng S, Johnsen H, Pesich R, Geisler S, Demeter J, Perou CM, Lonning PE, Brown PO, Borresen-Dale AL, Botstein D (2003) Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 100:8418–8423

    Article  PubMed  CAS  Google Scholar 

  • Takahashi M, Tonoki H, Tada M, Kashiwazaki H, Furuuchi K, Hamada J, Fujioka Y, Sato Y, Takahashi H, Todo S, Sakuragi N, Moriuchi T (2000) Distinct prognostic values of p53 mutations and loss of estrogen receptor and their cumulative effect in primary breast cancers. Int J Cancer 89:92–99

    Article  PubMed  CAS  Google Scholar 

  • Temam S, Flahault A, Perie S, Monceaux G, Coulet F, Callard P, Bernaudin JF, St Guily JL, Fouret P (2000) p53 gene status as a predictor of tumor response to induction chemotherapy of patients with locoregionally advanced squamous cell carcinomas of the head and neck. J Clin Oncol 18:385–394

    PubMed  CAS  Google Scholar 

  • Tomizawa Y, Kohno T, Fujita T, Kiyama M, Saito R, Noguchi M, Matsuno Y, Hirohashi S, Yamaguchi N, Nakajima T, Yokota J (1999) Correlation between the status of the p53 gene and survival in patients with stage I non-small cell lung carcinoma [In Process Citation]. Oncogene 18:1007–1014

    Article  PubMed  CAS  Google Scholar 

  • Tomizawa Y, Kohno T, Kondo H, Otsuka A, Nishioka M, Niki T, Yamada T, Maeshima A, Yoshimura K, Saito R, Minna JD, Yokota J (2002) Clinicopathological significance of epigenetic inactivation of RASSF1A at 3p21.3 in stage I lung adenocarcinoma. Clin Cancer Res 8:2362–2368

    PubMed  CAS  Google Scholar 

  • Troester MA, Herschkowitz JI, Oh DS, He X, Hoadley KA, Barbier CS, Perou CM (2006) Gene expression patterns associated with p53 status in breast cancer. BMC Cancer 6:276

    Article  PubMed  Google Scholar 

  • Wahl AF, Donaldson KL, Fairchild C, Lee FY, Foster SA, Demers GW, Galloway DA (1996) Loss of normal p53 function confers sensitization to Taxol by increasing G2/M arrest and apoptosis. Nat Med 2:72–79

    Article  PubMed  CAS  Google Scholar 

  • Whibley C, Pharoah PD, Hollstein M (2009) p53 polymorphisms: cancer implications. Nat Rev Cancer 9:95–107

    Article  PubMed  CAS  Google Scholar 

  • Yamasaki M, Miyata H, Fujiwara Y, Takiguchi S, Nakajima K, Nishida T, Yasuda T, Matsuyama J, Mori M, Doki Y (2010) p53 genotype predicts response to chemotherapy in patients with squamous cell carcinoma of the esophagus. Ann Surg Oncol 17:634–642

    Article  PubMed  Google Scholar 

  • Zawlik I, Kita D, Vaccarella S, Mittelbronn M, Franceschi S, Ohgaki H (2009) Common polymorphisms in the MDM2 and TP53 genes and the relationship between TP53 mutations and patient outcomes in glioblastomas. Brain Pathol 19:188–194

    Article  PubMed  CAS  Google Scholar 

  • Zhang J, Yang PL, Gray NS (2009) Targeting cancer with small molecule kinase inhibitors. Nat Rev Cancer 9:28–39

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Group of Molecular Mechanisms and Biomarkers, International Agency for Research on Cancer (CIRC/IARC), 150 Cours Albert Thomas, 69372, Lyon, France

    Magali Olivier

Authors
  1. Magali Olivier
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Magali Olivier .

Editor information

Editors and Affiliations

  1. International Prevention Research Instit, 95 cours Lafayette, Lyon, 69006, France

    Pierre Hainaut

  2. International Agency for Cancer Research, 150 Cours Albert-Thomas, Lyon, 69372, France

    Magali Olivier

  3. Cancer Center Karolinska (CCK), Dept. Oncology and Pathology, Karolinska Institute, Karolinska Institutet, Stockholm, 171 76, Sweden

    Klas G. Wiman

Rights and permissions

Reprints and permissions

Copyright information

© 2013 Springer Science+Business Media New York

About this chapter

Cite this chapter

Olivier, M. (2013). TP53 Somatic Mutations: Prognostic and Predictive Value in Human Cancers. In: Hainaut, P., Olivier, M., Wiman, K. (eds) p53 in the Clinics. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-3676-8_8

Download citation

Publish with us

Policies and ethics

Search

Navigation